Caraco plant fixes delayed in Detroit

Caraco Pharmaceutical Laboratories is still working to fix manufacturing troubles at its Detroit facility and won't be able to resume manufacturing there by the end of fiscal 2011 as previously expected. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.